AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

Researchers at the Duke Human Vaccine Institute successfully created an HIV vaccine candidate that guides key immune cells ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Scientists at Duke University's Human Vaccine Institute have made a significant advance in the quest for an HIV vaccine.

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer drug candidate outside China.

The Pharmaceutical Technology Excellence Awards winners have been announced! Download our full 50+ page report to find out ...

1 月 24 日，赛诺菲宣布其 CD38 单抗「艾沙妥昔单抗」新适应症在国内获批上市，用于与硼替佐米、来那度胺和地塞米松 (VRd)联合，治疗不适合自体干细胞移植 (ASCT)的新诊断的多发性骨髓瘤 (NDMM)成人患者。

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...